PHOSP-I

This study is investigating whether Tocilizumab, a medication currently used to treat people in hospital with Covid-19, can help reduce symptoms of long Covid.

Tocilizumab is an anti-inflammatory medication that has been used for many years. This study will test whether treating people with symptoms of long Covid such as fatigue, fever, joint or muscle pain and ongoing inflammation, will help them feel better.

This study is part of PHOSP-COVID (post-hospitalisation Covid-19), a consortium of leading researchers and clinicians across the UK working together to understand and improve long-term health outcomes for people who have had Covid-19. It is led by a team of researchers at the University of Leicester and University Hospitals of Leicester NHS Trust under the umbrella of NIHR Leicester Biomedical Research Centre.

This study is taking place at several sites across England. Research for the Future is currently supporting recruitment at the following locations: Salford Royal Hospital